Recent Company News

• 08:01 AM ET May 18, 2026
  

  Can-Fite BioPharma announces peer-reviewed publication on piclidenoson for canine osteoarthritis in Frontiers in Veterinary Science study (543.00a, +24.00)

• 09:18 AM ET May 13, 2026
  

  Can-Fite BioPharma upgraded to buy from hold at D. Boral Capital ($3.39, 0.00)

• 07:05 AM ET May 13, 2026
  

  Can-Fite BioPharma announced plans to advance its pancreatic cancer program into a Phase 2B study evaluating Namodenoson in combination with immunotherapy (480.00a, 0.00)

• 06:35 PM ET May 06, 2026
  

  Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million

• 08:37 AM ET Apr 30, 2026
  

  Can-Fite BioPharma reports positive phase 2a data with Namodenoson in pancreatic cancer; 35% of patients remain on therapy, including one beyond 16 months (454.00a, +4.00)

• 02:00 PM ET Apr 06, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 30-Mar

• 06:26 AM ET Mar 31, 2026
  

  Can-Fite BioPharma holders file to place up to 3.3M shares (1.6M ADSs) through H.C. Wainwright (494.00a, -23.00)

• 07:23 AM ET Mar 30, 2026
  

  Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix (530.00a, +7.00)

• 09:34 AM ET Mar 26, 2026
  

  Can-Fite BioPharma reports FY net income ($9.8M) vs FactSet ($8.9M) [1 est] (508.00a, -7.00)

• 07:50 AM ET Mar 17, 2026
  

  Can-Fite BioPharma secures Israeli patent for A3AR-based fat loss therapy, including lead drug Namodenoson (605.00a, +27.00)